Literature DB >> 23884038

Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.

Naila Makhani1, Bo-yee Ngan, Binita M Kamath, E Ann Yeh.   

Abstract

Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,(1-4) but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23884038      PMCID： PMC3908464          DOI： 10.1212/WNL.0b013e3182a2cc4a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

1.  Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.

Authors:  C Heesen; J Gbadamosi; B G Schoser; D Pöhlau
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

2.  Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.

Authors:  A Frese; F Bethke; P Lüdemann; F Stögbauer
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

3.  Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.

Authors:  Mathew Pulicken; Ayman Koteish; Karen DeBusk; Peter A Calabresi
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

4.  Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.

Authors:  Helmut Neumann; Antal Csepregi; Michael Sailer; Peter Malfertheiner
Journal:  J Neurol       Date:  2007-03-12       Impact factor: 4.849

Review 5.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

6.  Glatiramer acetate induced hepatotoxicity.

Authors:  K Subramaniam; P Pavli; H Llewellyn; S Chitturi
Journal:  Curr Drug Saf       Date:  2012-04

7.  Acute hepatitis induced by glatiramer acetate.

Authors:  Pierre Deltenre; Marie-Odile Peny; André Dufour; Mohamed El Nady; Jean Henrion
Journal:  BMJ Case Rep       Date:  2009-02-27
  7 in total
  8 in total

Review 1.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

2.  First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.

Authors:  Charalampos Skarlis; Nikolaos Markoglou; Maria Gontika; Anastasia Bougea; Serafeim Katsavos; Artemios Artemiadis; George Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2022-10-05       Impact factor: 3.830

Review 3.  Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Authors:  Rebecca S Farber; Ilana K Sand
Journal:  Ther Adv Neurol Disord       Date:  2015-09       Impact factor: 6.570

Review 4.  Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments.

Authors:  Colin Wilbur; E Ann Yeh
Journal:  Paediatr Drugs       Date:  2019-06       Impact factor: 3.930

Review 5.  Liver injury and glatiramer acetate, an uncommon association: case report and literature review.

Authors:  Javier Almeida; Nuria Solà-Valls; Elisa Pose; Yolanda Blanco; María Sepúlveda; Sara Llufriu; Pere Gines; Albert Saiz
Journal:  Ther Adv Neurol Disord       Date:  2017-07-26       Impact factor: 6.570

Review 6.  Use of Disease-Modifying Therapies in Pediatric MS.

Authors:  Marta Simone; Tanuja Chitnis
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.972

Review 7.  Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.

Authors:  Dejan Jakimovski; Samreen Awan; Svetlana P Eckert; Osman Farooq; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-12-23       Impact factor: 5.749

Review 8.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.